Evidence map›Paper›PMID 28067027›Full record

ArticleProteomics2017

High-density lipoproteins in high resolution: Will proteomics solve the paradox for cardiovascular risk?

Ferheen Baig, Abhishek Joshi, Manuel Mayr

Abstract readComment
PubMed Publisher
In one paragraph

Article in Proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Ferheen BaigKing's British Heart Foundation Centre, King's College London, London, UK.
Abhishek JoshiKing's British Heart Foundation Centre, King's College London, London, UK.
Manuel MayrKing's British Heart Foundation Centre, King's College London, London, UK.

Funding

British Heart Foundation CH/16/3/32406British Heart Foundation FS/13/2/29892British Heart Foundation FS/16/32/32184British Heart Foundation RG/16/14/32397
6 · The paper itself

Abstract

While lipid abnormalities continue to account for over 60% of the population attributable risk for myocardial infarction, the well-known inverse correlation between plasma high-density lipoprotein (HDL) cholesterol and cardiovascular risk has failed to deliver clinically useful therapeutic interventions. Thus, there is an unmet need to better understand the function of different HDL particles. Targeted, high-resolution lipoproteomics provides an innovative approach to studying the kinetics of HDL particles. In this commentary, we discuss the development of an informatics platform for increased throughput and highlight how this approach delivers the potential for novel, hybrid instrument technologies to inform clinical dyslipidemia studies.

Indexed as

Cardiovascular DiseasesHigh-Throughput Screening AssaysHumansLipoproteins, HDLProteomicsLipoproteins, HDLBiomarkerCardiovascular systemCholesterolHeart diseaseTherapiesVascular disease

Identifiers

PMID28067027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.